---
created: 2025-04-13
updated: 2025-04-13T10:53
id: E&o;afyTYO
specialty: immuno
specialty_id: 253
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies::nivolumab
  - "source/ak-step1-v11:": 
  - theme/firstaid::04-pathology::03-neoplasia::05-immune-checkpoint-interactions
  - "source/ak-step1-v11:": 
  - theme/firstaid::04-pathology::03-neoplasia::05-immune-checkpoint-interactions::nivolumab
  - "source/ak-step1-v11:": 
  - source/ome-banner
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::miscellaneous-pharm::akadds
  - source/ak-step1-v11::$ankingadds::fa2020::pathology
  - source/ak-step1-v11::^other::^highyield::1-highyield"
type: flashcard
---

# Question
Nivolumab is an anti-checkpoint monoclonal antibody that binds to **PD-1** on T cells

---

# Answer
